Physician profile
Nermeen Botros
NPI 1114440229
$2,068.27
in general payments reported to CMS, 2019-2025
20 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $120 · 2021: $433 · 2022: $194 · 2023: $304 · 2024: $406 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $464.64 | 2021-2025 | Lifevest |
| Abbvie INC. | $287.18 | 2023-2025 | Dalvance, Avycaz |
| Astrazeneca Pharmaceuticals LP | $251.65 | 2020-2025 | Airsupra, Farxiga |
| Pfizer INC. | $159.72 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $146.57 | 2023-2024 | Xarelto |
| Vifor Pharma, INC. | $135.09 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $113.51 | 2021-2023 | Lupkynis |
| Kestra Medical Technology Services, INC. | $101.36 | 2025 | Assure Wcd |
| Opko Pharmaceuticals, LLC | $50.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.36 | 2021-2022 | |
| Glaxosmithkline, LLC. | $47.02 | 2021 | |
| Novo Nordisk INC | $45.05 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $43.05 | 2021-2022 | |
| Abbott Laboratories | $31.42 | 2025 | Cardiomems |
| Scpharmaceuticals INC. | $30.82 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.42 | 2024 | Gardasil, Gardasil 9 |
| Paratek Pharmaceuticals, INC. | $23.88 | 2025 | Nuzyra |
| Shield Therapeutics INC | $23.33 | 2025 | |
| Philips North America LLC | $21.56 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nermeen Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.